Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A
Chromothripsis, the process of catastrophic shattering and haphazard repair of chromosomes, is a common event in cancer. Whether chromothripsis might constitute an actionable molecular event amenable to therapeutic targeting remains an open question. We describe recurrent chromothripsis of chromosome 21 in a subset of patients in blast phase of a myeloproliferative neoplasm (BP-MPN), which alongside other structural variants leads to amplification of a region of chromosome 21 in ∼25% of patients ('chr21amp'). We report that chr21amp BP-MPN has a particularly aggressive and treatment-resistant phenotype. The chr21amp event is highly clonal and present throughout the hematopoietic hierarchy. DYRK1A , a serine threonine kinase and transcription factor, is the only gene in the 2.7Mb minimally amplified region which showed both increased expression and chromatin accessibility compared to non-chr21amp BP-MPN controls. We demonstrate that DYRK1A is a central node at the nexus of multiple cellular functions critical for BP-MPN development, including DNA repair, STAT signalling and BCL2 overexpression. DYRK1A is essential for BP-MPN cell proliferation in vitro and in vivo , and DYRK1A inhibition synergises with BCL2 targeting to induce BP-MPN cell apoptosis. Collectively, these findings define the chr21amp event as a prognostic biomarker in BP-MPN and link chromothripsis to a druggable target.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2023) vom: 10. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brierley, C K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 18.12.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.12.08.570880 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365968927 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365968927 | ||
| 003 | DE-627 | ||
| 005 | 20231227134221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.12.08.570880 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1231.xml |
| 035 | |a (DE-627)NLM365968927 | ||
| 035 | |a (NLM)38106192 | ||
| 035 | |a (PII)2023.12.08.570880 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brierley, C K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Chromothripsis, the process of catastrophic shattering and haphazard repair of chromosomes, is a common event in cancer. Whether chromothripsis might constitute an actionable molecular event amenable to therapeutic targeting remains an open question. We describe recurrent chromothripsis of chromosome 21 in a subset of patients in blast phase of a myeloproliferative neoplasm (BP-MPN), which alongside other structural variants leads to amplification of a region of chromosome 21 in ∼25% of patients ('chr21amp'). We report that chr21amp BP-MPN has a particularly aggressive and treatment-resistant phenotype. The chr21amp event is highly clonal and present throughout the hematopoietic hierarchy. DYRK1A , a serine threonine kinase and transcription factor, is the only gene in the 2.7Mb minimally amplified region which showed both increased expression and chromatin accessibility compared to non-chr21amp BP-MPN controls. We demonstrate that DYRK1A is a central node at the nexus of multiple cellular functions critical for BP-MPN development, including DNA repair, STAT signalling and BCL2 overexpression. DYRK1A is essential for BP-MPN cell proliferation in vitro and in vivo , and DYRK1A inhibition synergises with BCL2 targeting to induce BP-MPN cell apoptosis. Collectively, these findings define the chr21amp event as a prognostic biomarker in BP-MPN and link chromothripsis to a druggable target | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Yip, B H |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, G |e verfasserin |4 aut | |
| 700 | 1 | |a Goyal, H |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, S |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, J |e verfasserin |4 aut | |
| 700 | 1 | |a Levine, M F |e verfasserin |4 aut | |
| 700 | 1 | |a Jakobsdottir, G M |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Meira, A |e verfasserin |4 aut | |
| 700 | 1 | |a Adamo, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bashton, M |e verfasserin |4 aut | |
| 700 | 1 | |a Hamblin, A |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, S A |e verfasserin |4 aut | |
| 700 | 1 | |a O'Sullivan, J |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, L |e verfasserin |4 aut | |
| 700 | 1 | |a Olijnik, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Cotton, A |e verfasserin |4 aut | |
| 700 | 1 | |a Narina, S |e verfasserin |4 aut | |
| 700 | 1 | |a Pruett-Miller, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Enshaei, A |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, C |e verfasserin |4 aut | |
| 700 | 1 | |a Drummond, M |e verfasserin |4 aut | |
| 700 | 1 | |a Knapper, S |e verfasserin |4 aut | |
| 700 | 1 | |a Tefferi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Antony-Debré, I |e verfasserin |4 aut | |
| 700 | 1 | |a Thongjuea, S |e verfasserin |4 aut | |
| 700 | 1 | |a Wedge, D C |e verfasserin |4 aut | |
| 700 | 1 | |a Constantinescu, S |e verfasserin |4 aut | |
| 700 | 1 | |a Papaemmanuil, E |e verfasserin |4 aut | |
| 700 | 1 | |a Psaila, B |e verfasserin |4 aut | |
| 700 | 1 | |a Crispino, J D |e verfasserin |4 aut | |
| 700 | 1 | |a Mead, A J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2023) vom: 10. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:10 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.12.08.570880 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 10 |c 12 | ||